RA0693

antibody from Oursmab

Targeting: SLC39A6 LIV-1

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0693

Provider

Oursmab

Product name

Ladiratuzumab (Biosimilar Reference Antibody) (SLC39A6)

Antibody type

Monoclonal

Description

Ladiratuzumab (also known as SGN-LIV1A) is an investigational antibody-drug conjugate (ADC) developed by Seagen. It consists of a humanized monoclonal antibody targeting LIV-1 (SLC39A6) linked to a potent microtubule-disrupting payload, monomethyl auristatin E (MMAE), via a protease-cleavable linker. Upon binding to LIV-1 on the cancer cell surface, the ADC is internalized, the linker is cleaved, and the cytotoxic payload is released inside the cell, leading to cell cycle arrest and apoptosis. Ladiratuzumab has been primarily investigated in clinical trials for the treatment of metastatic triple-negative breast cancer (TNBC), leveraging the high and frequent expression of LIV-1 in this aggressive disease.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.